Immuneering Corp (IMRX)
1.56
+0.03
(+1.96%)
USD |
NASDAQ |
May 02, 16:00
1.60
+0.04
(+2.56%)
After-Hours: 07:53
Immuneering Cash from Operations (TTM): -48.97M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -48.97M |
| September 30, 2023 | -48.94M |
| June 30, 2023 | -47.54M |
| March 31, 2023 | -46.24M |
| December 31, 2022 | -44.10M |
| September 30, 2022 | -41.59M |
| June 30, 2022 | -40.00M |
| Date | Value |
|---|---|
| March 31, 2022 | -36.99M |
| December 31, 2021 | -30.85M |
| September 30, 2021 | -27.06M |
| June 30, 2021 | -21.52M |
| March 31, 2021 | -18.45M |
| December 31, 2020 | -14.62M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-48.97M
Minimum
Dec 2023
-14.62M
Maximum
Dec 2020
-35.91M
Average
-40.00M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
| Geron Corp | -167.74M |
| SELLAS Life Sciences Group Inc | -31.41M |
| Elicio Therapeutics Inc | -- |
| Vistagen Therapeutics Inc | -26.09M |
| ADMA Biologics Inc | 8.80M |